Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NG101m in newly diagnosed glioblastoma multiforme
NCT04373785Phase 2Not yet recruiting
- Sponsor
- NeuGATE Theranostics
- Start
- Jan 2027
- Primary completion
- Jul 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NG101m in glioblastoma multiforme (GBM), sponsored by NeuGATE Theranostics. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
NG101m
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT04373785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04373785.